Detalles de la búsqueda
1.
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Cell
; 186(16): 3476-3498.e35, 2023 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37541199
2.
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Cell
; 187(4): 1016, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38364782
3.
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Genes Dev
; 31(3): 318-332, 2017 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28242626
4.
A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
Gynecol Oncol
; 185: 83-94, 2024 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38377762
5.
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
Oncologist
; 28(3): 252-257, 2023 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36718018
6.
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Gynecol Oncol
; 172: 82-91, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37001446
7.
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
Gynecol Oncol
; 171: 141-150, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898292
8.
Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
Gynecol Oncol
; 171: 151-158, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36905875
9.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol
; 178: 119-129, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37862791
10.
DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer.
BMC Bioinformatics
; 23(1): 321, 2022 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35931981
11.
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
Gynecol Oncol
; 167(3): 423-428, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36244829
12.
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Gynecol Oncol
; 164(2): 245-253, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34906376
13.
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
Int J Clin Oncol
; 27(12): 1881-1890, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36344654
14.
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(9): 1275-1289, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34363762
15.
Inhibition of Kpnß1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer.
BMC Cancer
; 21(1): 106, 2021 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33530952
16.
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
Gynecol Oncol
; 162(3): 661-666, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34243976
17.
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
Gynecol Oncol
; 161(2): 382-388, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33712274
18.
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
Int J Cancer
; 147(2): 413-422, 2020 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31714586
19.
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Gynecol Oncol
; 156(2): 301-307, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31870556
20.
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Gynecol Oncol
; 157(1): 161-166, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31924334